GILD News 96.88 10/17/2014 05:00:23 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 96.88 $GILD

Final Glance: Biotechnology companies
AP - Thu Oct 16, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)

Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C
CNW Group - Thu Oct 16, 1:44PM CDT
-- Harvoni Provides High Cure Rates (SVR12), Shortens Treatment Duration and Eliminates Need for Interferon and Ribavirin --
GILD: 96.88 (+0.72)

Health Canada Issues Notice of Compliance for Gilead's Harvoni(TM) (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Business Wire - Thu Oct 16, 12:30PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Harvoni(TM) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single table regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, granted marketing authorization under the tradename Sovaldi(R) in December 2013. The efficacy of Harvoni has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naive patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.
GILD: 96.88 (+0.72)

Midday Glance: Biotechnology companies
AP - Thu Oct 16, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)

Early Glance: Biotechnology companies
AP - Thu Oct 16, 10:35AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)

3 Reasons AbbVie's Stock Could Rise
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 16, 7:02AM CDT
Finding reasons to worry about AbbVie 's stock isn't too hard these days. Shares have dropped over 7% in the last few weeks -- and that was before the latest cause for uneasiness. The pharmaceutical company's board just announced that it is...
GILD: 96.88 (+0.72), SHPG: 178.46 (+7.97), ABBV: 52.90 (-1.73)

Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 92.54 (+2.91), EBS: 21.24 (+0.35), GILD: 96.88 (+0.72), NVAX: 5.16 (+0.47)

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 101.26 (+0.16), ALNY: 84.94 (+0.55), GILD: 96.88 (+0.72), SRPT: 22.30 (+1.39), AUXL: 30.35 (-0.06), AMGN: 130.45 (-0.45), ABBV: 52.90 (-1.73)

Should Gilead Sciences, inc. Fear Incoming Competition?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 12:17PM CDT
Gilead Sciences ' shares have tumbled more than 8% in the past week as investors digest the FDA approval of its second-generation hepatitis C drug Harvoni and the potential competitive threats from AbbVie and Bristol-Myers Squibb . ...
GILD: 96.88 (+0.72), ABBV: 52.90 (-1.73), BMY: 49.22 (+0.26)

Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary
Sweta Killa - ZACKS - Wed Oct 15, 12:00PM CDT
Investors should take a close look to healthcare ETFs following Johnson & Johnson earnings beat.
JNJ: 96.78 (-1.43), PPH: 58.24 (-0.34), IYH: 126.91 (-0.17), GILD: 96.88 (+0.72), ABBV: 52.90 (-1.73), XLV: 60.21 (-0.31)

Jim Cramer on Stocks and Investing: Why I Hate This Market
at The Street - Wed Oct 15, 10:21AM CDT
Because it’s completely hit or miss.
JNJ: 96.78 (-1.43), SWKS: 51.53 (+1.93), GILD: 96.88 (+0.72), DOW: 44.76 (+0.67)

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
at The Street - Wed Oct 15, 8:35AM CDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
SGEN: 34.73 (+1.40), GILD: 96.88 (+0.72)

Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 226.35 (-3.35), GILD: 96.88 (+0.72), DDD: 40.90 (-0.37), TKMR: 22.81 (-1.09), TASR: 14.97 (+0.28)

'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks
at The Street - Wed Oct 15, 4:00AM CDT
The trading panel discussed whether margin calls are weighing on the energy sector and which technology stocks to consider.
F: 13.98 (+0.36), SWKS: 51.53 (+1.93), AMGN: 130.45 (-0.45), SOXX: 77.60 (+1.18), INTC: 30.85 (-0.42), PANW: 97.88 (+0.45), JNPR: 19.19 (+0.06), COH: 35.12 (-0.42), EBAY: 47.88 (-2.36), GILD: 96.88 (+0.72), GWPH: 63.09 (+1.54), DPZ: 83.93 (+0.28), GOOGL: 536.92 (-3.81), CP: 193.81 (+6.69), MELI: 105.94 (-0.22), CSCO: 22.82 (-0.14), KING: 11.31 (-0.07)

J&J raises outlook on Q3 beat
at Investor's Business Daily - Tue Oct 14, 5:51PM CDT
The medical giant's earnings, ex items, rose 10% to $1.50 a share, beating analysts' estimates by 5 cents. Sales climbed 5% to $18.47 bil, $90 mil ahead of consensus. Johnson & Johnson (JNJ) raised its full-year EPS guidance to $5.92-$5.97, on the...
JNJ: 96.78 (-1.43), GILD: 96.88 (+0.72)

Gilead
at Investor's Business Daily - Tue Oct 14, 5:49PM CDT
Gilead (GILD) shares fell 4.2% to 97.18 as light sales of J&J's Olysio could imply that Sovaldi sales may also come in light. Comments by J&J executives that they will work to make Olysio accessible and competitive in light of the recent approval of...
GILD: 96.88 (+0.72)

Wall Street Ends Mixed; Airlines Soar As Oil Plunges
at Investor's Business Daily - Tue Oct 14, 4:09PM CDT
Stocks ended mixed Tuesday after trimming early gains. Volume crept higher. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2%, and the Dow Jones industrial average slipped a fraction. Preliminary data showed that volume rose slightly on the NYSE and the...
NFLX: 361.70 (-86.89), SWKS: 51.53 (+1.93), GILD: 96.88 (+0.72), DAL: 33.32 (+0.94), DPZ: 83.93 (+0.28), BAC: 16.08 (+0.32), SCHW: 25.50 (+0.18), URI: 99.64 (+6.21), LUV: 30.94 (+0.92)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
SHIFTAIon Puts Governance at Center of AI Migration

Updated Category News Views 0

Legacy code is where grand AI promises usually go to get mugged by reality. ACL Digital’s new SHIFTAIon platform is taking a sensible swing at that ugly problem: not merely generating code faster, but putting discovery, architecture decisions, testing, security checks, reviewer signoffs, and reporting into one controlled modernization process. That distinction matters....

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 54

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 159

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

GRAX Honored as Cybersecurity Innovator by BostInno Awards

Updated Category News Views 66

GRAX Recognized as a Leader in Cybersecurity GRAX, Inc., well-known for its innovation in Salesforce data management and protection, has recently earned an esteemed recognition as a 2024 Fire honoree in cybersecurity from BostInno. This award celebrates companies that are driving innovation in the Boston area, emphasizing GRAX's role as a pioneer in data security....

Continue Reading
i2Cool and Marubeni Join Forces for Revolutionary Cooling Tech

Updated Category News Views 286

i2Cool and Marubeni Forge Strategic Partnership i2Cool, a pioneering company in the realm of electricity-free cooling technology, has established a significant global partnership with Marubeni, a prominent trading company from Japan. This collaboration is designed to facilitate the widespread adoption of electricity-free cooling technologies, concentrating particularly on...

Continue Reading
Jasper Therapeutics Upcoming Investor Conferencs - September 2024

Updated Category News Views 82

Jasper Therapeutics to Showcase Innovations at September Events Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic...

Continue Reading
Tech Sector Thrives as Meta Drives Nasdaq-100 to New Heights

Updated Category News Views 303

Tech Sector Soars with New Nasdaq-100 Records The Nasdaq-100 has reached an unprecedented high of 22,191.37, highlighting the unyielding strength of tech stocks. The renowned Invesco QQQ Trust (NASDAQ: QQQ) has also achieved a 52-week peak, reaching $540, demonstrating the energetic rally across the technology market. Meta Platforms Inc's Remarkable Performance Meta...

Continue Reading
Millicom Advances Infrastructure Sale and Special Dividend Plans

Updated Category News Views 207

Millicom Announces Infrastructure Deal Progress Millicom International Cellular S.A. (NASDAQ: TIGO) has made significant strides in its transaction with SBA Communications. The company recently revealed the partial closing of its sale involving LATI International S.A., the holding company for its mobile passive infrastructure assets in Central America. This deal has...

Continue Reading